News and Trends 31 May 2017
Swiss Biotech raises €10M to Target Elusive Protein Interactions in Cancer
Inthera Bioscience has raised €9.6M in Series A to complete preclinical phase of its lead cancer program and expand its pipeline. Inthera Bioscience, located in Zurich, has closed a €9.6M (CHF 10.5M) Series A round led by Merck Ventures and backed by Novo Seeds and BioMedical Ventures, as well as a private investor. Members of Novo Seeds and […]